Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
boston blog main
3
×
boston top stories
clinical trials
life sciences
national blog main
3
×
san diego blog main
biotech
boston
dyne therapeutics
myotonic dystrophy type 1
national top stories
new york blog main
rare disease drugs
san diego top stories
akcea therapeutics
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech ipos
bluebird bio
cardiomyopathy
drugs
duchenne muscular dystrophy
facioscapulohumeral muscular dystrophy
fda
gene therapy
inotersen
joshua brumm
kaleido biosciences
metacrine
muscular dystrophy
neuropathy
new york
new york top stories
nonalcoholic steatohepatitis
onpattro
patisiran
pfizer
What
drug
genetic
medicines
rare
3
×
ago
dyne
ipo
muscle
therapeutics
akcea
alnylam
amyloidosis
approved
attr
available
battle
biotechs
brings
company
considering
data
debilitating
developing
disease
diseases
disorders
dyne’s
early
expected
experimental
eyes
fda
having
humans
ipos
long
million
muscular
oks
patients
Language
unset
Current search:
rare
×
photo
×
" national blog main "
×
" boston blog main "
×
@xconomy.com
4 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea